Literature DB >> 19428246

20(R)-ginsenoside Rh2, not 20(S), is a selective osteoclastgenesis inhibitor without any cytotoxicity.

Jie Liu1, Jun Shiono, Kuniyoshi Shimizu, Hongshan Yu, Chunzhi Zhang, Fengxie Jin, Ryuichiro Kondo.   

Abstract

Increased osteoclastic bone resorption plays a central role in the pathogenesis of many bone diseases, and osteoclast inhibitors are the most widely used treatments for these diseases. Ginsenosides, the main component of ginseng, have been known for their medicinal effects such as anti-inflammatory and anti-proliferative activities. In this study, we investigated the inhibitory effects of ginsenosides (ginsenoside 20(R)-Rh2 and ginsenoside 20(S)-Rh2) on osteoclastgenesis using RAW264 cells in vitro. Only ginsenoside 20(R)-Rh2 showed selective osteoclastgenesis inhibitory activity without any cytotoxicity up to 100 microM. These results implied that the stereochemistry of the hydroxyl group at C-20 may play an important role in selective osteoclastgenesis inhibitory activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19428246     DOI: 10.1016/j.bmcl.2009.04.054

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  19 in total

1.  Skin anti-photoaging properties of ginsenoside Rh2 epimers in UV-B-irradiated human keratinocyte cells.

Authors:  Sun-Joo Oh; Sihyeong Lee; Woo-Yong Choi; Chang-Jin Lim
Journal:  J Biosci       Date:  2014-09       Impact factor: 1.826

Review 2.  Ginsenosides from American ginseng: chemical and pharmacological diversity.

Authors:  Lian-Wen Qi; Chong-Zhi Wang; Chun-Su Yuan
Journal:  Phytochemistry       Date:  2011-03-09       Impact factor: 4.072

3.  Stereoselective regulations of P-glycoprotein by ginsenoside Rh2 epimers and the potential mechanisms from the view of pharmacokinetics.

Authors:  Jingwei Zhang; Fang Zhou; Fang Niu; Meng Lu; Xiaolan Wu; Jianguo Sun; Guangji Wang
Journal:  PLoS One       Date:  2012-04-18       Impact factor: 3.240

4.  Neuroprotective effects of ginsenosides Rh1 and Rg2 on neuronal cells.

Authors:  Xiao-Fan Li; Cathy Nga-Ping Lui; Zhi-Hong Jiang; Yung Kin-Lam Ken
Journal:  Chin Med       Date:  2011-05-19       Impact factor: 5.455

Review 5.  Stereoisomers of Saponins in Panax notoginseng (Sanqi): A Review.

Authors:  Ming Peng; Ya X Yi; Tong Zhang; Yue Ding; Jian Le
Journal:  Front Pharmacol       Date:  2018-03-13       Impact factor: 5.810

6.  Ginsenoside Rg3 stereoisomers differentially inhibit vascular smooth muscle cell proliferation and migration in diabetic atherosclerosis.

Authors:  Mengqi Guo; Guanlun Guo; Jie Xiao; Xi Sheng; Xinyu Zhang; Yuanyuan Tie; Yuen-Kit Cheng; Xiaoping Ji
Journal:  J Cell Mol Med       Date:  2018-03-22       Impact factor: 5.310

Review 7.  Ginseng saponins and the treatment of osteoporosis: mini literature review.

Authors:  Muhammad Hanif Siddiqi; Muhammad Zubair Siddiqi; Sungeun Ahn; Sera Kang; Yeon-Ju Kim; Natarajan Sathishkumar; Dong-Uk Yang; Deok-Chun Yang
Journal:  J Ginseng Res       Date:  2013-07       Impact factor: 6.060

8.  Effect of Korean Red Ginseng on radiation-induced bone loss in C3H/HeN mice.

Authors:  Jin-Hee Lee; Hae-June Lee; Miyoung Yang; Changjong Moon; Jong-Choon Kim; Chun-Sik Bae; Sung-Kee Jo; Jong-Sik Jang; Sung-Ho Kim
Journal:  J Ginseng Res       Date:  2013-10       Impact factor: 6.060

9.  Stereoselective property of 20(S)-protopanaxadiol ocotillol type epimers affects its absorption and also the inhibition of P-glycoprotein.

Authors:  Wenyan Wang; Xiangmeng Wu; Li Wang; Qingguo Meng; Wanhui Liu
Journal:  PLoS One       Date:  2014-06-02       Impact factor: 3.240

10.  Rh2E2, a novel metabolic suppressor, specifically inhibits energy-based metabolism of tumor cells.

Authors:  Vincent Kam Wai Wong; Hang Dong; Xu Liang; Li-Ping Bai; Zhi-Hong Jiang; Yue Guo; Ah Ng Tony Kong; Rui Wang; Richard Kin Ting Kam; Betty Yuen Kwan Law; Wendy Wen Luen Hsiao; Ka Man Chan; Jingrong Wang; Rick Wai Kit Chan; Jianru Guo; Wei Zhang; Feng Gen Yen; Hua Zhou; Elaine Lai Han Leung; Zhiling Yu; Liang Liu
Journal:  Oncotarget       Date:  2016-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.